HLS Therapeutics Inc. (TSX:HLS)

Market Cap	163.88M
Revenue (ttm)	76.95M
Net Income (ttm)	-20.52M
Shares Out	31.39M
EPS (ttm)	-0.65
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,115
Average Volume	7,435
Open	5.26
Previous Close	5.26
Day's Range	5.22 - 5.39
52-Week Range	3.00 - 5.48
Beta	1.11
RSI	65.40
Earnings Date	Aug 7, 2025

About HLS Therapeutics

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders, central nervous system, and cardiovascular disease in Canada, the United States, and internationally. The company’s lead products include Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care de...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Craig Millian
• Employees: 92
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: HLS

Financial Performance

In 2024, HLS Therapeutics's revenue was $56.62 million, a decrease of -10.23% compared to the previous year's $63.07 million. Losses were -$19.66 million, -28.61% less than in 2023.

Financial numbers in USD